Updated Jul 9, 10:52 PM · 60 sources analyzed
Key Takeaways
MapLight's schizophrenia Phase 2 is complete but data-free — the only thing that matters now is what the numbers show.
Keros Therapeutics terminated the TROPOS PAH Phase 2 trial for KER-012, a meaningful pipeline setback with no disclosed rationale.
Syndax's revumenib solid tumor program was terminated, capping the menin inhibitor's commercial potential to hematologic malignancies.
📉 Loser
Keros Therapeutics — Phase 2 TROPOS trial of KER-012 in PAH terminated with no data and no explanation, removing a key pipeline asset.
🔭 Watch Next
MapLight Therapeutics' topline ML-007C-MA efficacy data from the completed Phase 2 schizophrenia study is the most consequential pending readout visible in today's sources, with disclosure expected at a psychiatric congress or via press release in H2 2026.
MapLight Therapeutics Phase 2 schizophrenia study marked complete
MapLight Therapeutics' Phase 2 randomized, double-blind, placebo-controlled trial of ML-007C-MA in inpatient adults with schizophrenia has been marked completed on ClinicalTrials.gov. The registry update confirms the study finished enrollment and follow-up, but no efficacy or safety data have been released publicly. For a company targeting a crowded CNS space with a novel mechanism, the next move — disclosing whether the drug actually worked — is the only result that matters to investors.
ClinicalTrials.gov ↗Keros Therapeutics
KER-012 in Pulmonary Arterial Hypertension (PAH)
The TROPOS study, a Phase 2 double-blind, randomized, placebo-controlled trial of KER-012 added to background PAH therapy, has been marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released to explain the termination.
Why it matters
A terminated Phase 2 in PAH is a significant pipeline setback for Keros, whose thesis rested on demonstrating that modulating TGF-beta superfamily signaling could improve hemodynamics on top of standard-of-care. Investors will need to assess whether the termination reflects a safety signal, futility, or strategic reprioritization — and whether the company has sufficient remaining pipeline to sustain its valuation.
What to watch
Watch for Keros to disclose the reason for termination and provide a pipeline update, likely at an upcoming investor day or in quarterly earnings commentary in Q3 2026.
Sangamo CAR-Treg cell therapy study in living-donor kidney transplant marked complete
Sangamo Therapeutics' Phase 1/2 study of TX200-TR101 — chimeric antigen receptor-modified regulatory T-cells (CAR-Tregs, engineered immune cells designed to prevent organ rejection) — in living-donor kidney transplant recipients has been marked Completed on ClinicalTrials.gov, with no safety or efficacy data yet disclosed publicly.
Why it matters
Sangamo's CAR-Treg program has been one of the more scientifically novel assets in the transplant immunology space, and study completion means a data package should be forthcoming — the results will be closely watched by both transplant immunologists and cell therapy investors to determine whether the approach is feasible and safe enough to advance. A clean safety profile, even without formal efficacy endpoints at this stage, would be a meaningful de-risking event.
What to watch
Watch for Sangamo to present TX200-TR101 Phase 1/2 safety and immunological data at the American Transplant Congress or a comparable meeting in the second half of 2026.
MapLight Therapeutics
ML-007C-MA in Schizophrenia
The Phase 2 randomized, double-blind, placebo-controlled study (ML-007C-MA-211) in inpatient adults aged 18–64 has been marked Completed on ClinicalTrials.gov. Full efficacy and safety data have not yet been released.
Why it matters
Registry completion is a procedural marker, not a data readout — the investment story hinges entirely on what the efficacy numbers show. MapLight will need to demonstrate not just statistical separation from placebo but clinically meaningful improvement on validated symptom scales to justify further development in a space littered with late-stage failures.
What to watch
Watch for MapLight to release topline Phase 2 efficacy data or present at a psychiatric congress such as ACNP or SLAS in the second half of 2026.
Syndax Pharmaceuticals
Revumenib in Colorectal Cancer and Other Solid Tumors
The Phase 1/2 study of revumenib (a menin inhibitor) in participants with colorectal cancer or other solid tumors who had failed prior therapy has been marked Terminated on ClinicalTrials.gov. No antitumor activity or safety data have been disclosed to explain the termination.
Why it matters
Syndax's solid tumor expansion for revumenib appears to have stalled, reinforcing the view that menin inhibition's clinical utility may be confined to hematologic malignancies where the KMT2A fusion drives a clearer dependency. The termination does not affect the approved leukemia indication but does remove a potential growth vector that investors may have partially credited.
What to watch
Watch for Syndax to provide clarity on termination rationale during its next earnings call and whether any additional solid tumor indications remain under exploration for revumenib.
The Phase 2 randomized, double-blind, placebo-controlled study (ML-007C-MA-211) in inpatient adults aged 18–64 has been marked Completed on ClinicalTrials.gov. Full efficacy and safety data have not yet been released.
Why it matters
Schizophrenia is a high-value but high-failure CNS indication; whether ML-007C-MA demonstrated meaningful symptom reduction will determine whether MapLight can compete with established and emerging antipsychotics.
Analysis
Registry completion is a procedural marker, not a data readout — the investment story hinges entirely on what the efficacy numbers show. MapLight will need to demonstrate not just statistical separation from placebo but clinically meaningful improvement on validated symptom scales to justify further development in a space littered with late-stage failures.
What to watch
Watch for MapLight to release topline Phase 2 efficacy data or present at a psychiatric congress such as ACNP or SLAS in the second half of 2026.
The TROPOS study, a Phase 2 double-blind, randomized, placebo-controlled trial of KER-012 added to background PAH therapy, has been marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released to explain the termination.
Why it matters
PAH remains an underserved indication with multiple approved agents but limited options for refractory patients; a terminated Phase 2 removes KER-012 from the competitive landscape and raises questions about the activin receptor ligand trap mechanism in this disease.
Analysis
A terminated Phase 2 in PAH is a significant pipeline setback for Keros, whose thesis rested on demonstrating that modulating TGF-beta superfamily signaling could improve hemodynamics on top of standard-of-care. Investors will need to assess whether the termination reflects a safety signal, futility, or strategic reprioritization — and whether the company has sufficient remaining pipeline to sustain its valuation.
What to watch
Watch for Keros to disclose the reason for termination and provide a pipeline update, likely at an upcoming investor day or in quarterly earnings commentary in Q3 2026.
The Phase 1/2 study of revumenib (a menin inhibitor) in participants with colorectal cancer or other solid tumors who had failed prior therapy has been marked Terminated on ClinicalTrials.gov. No antitumor activity or safety data have been disclosed to explain the termination.
Why it matters
Revumenib is already approved in acute leukemia with KMT2A rearrangements; failure to extend the menin inhibitor mechanism into solid tumors narrows the commercial addressable market and limits label expansion upside.
Analysis
Syndax's solid tumor expansion for revumenib appears to have stalled, reinforcing the view that menin inhibition's clinical utility may be confined to hematologic malignancies where the KMT2A fusion drives a clearer dependency. The termination does not affect the approved leukemia indication but does remove a potential growth vector that investors may have partially credited.
What to watch
Watch for Syndax to provide clarity on termination rationale during its next earnings call and whether any additional solid tumor indications remain under exploration for revumenib.
The Phase 1/2 first-in-human study of SAR443579 — an investigational agent — across relapsed/refractory acute myeloid leukemia (AML, a blood cancer), B-cell acute lymphoblastic leukemia (B-ALL), high-risk myelodysplastic syndrome, and blastic plasmacytoid dendritic cell neoplasm has been marked Terminated on ClinicalTrials.gov. No efficacy or safety data explaining the termination have been released.
Why it matters
Early-phase terminations in hematologic oncology are common, but the breadth of indications studied here suggests SAR443579 was being evaluated as a platform asset; termination removes this candidate from Sanofi's heme-onc pipeline.
Analysis
For Sanofi, the termination of a first-in-human heme-onc program is a minor pipeline pruning event given the company's scale, but it signals that SAR443579 did not demonstrate a sufficient therapeutic window to warrant advancement — a pattern worth tracking as Sanofi works to rebuild its oncology presence. The lack of disclosed data makes it impossible to determine whether this was a safety or efficacy decision.
What to watch
Watch for any Sanofi oncology pipeline update at ASCO or ASH 2026 that may clarify the termination rationale and highlight replacement heme-onc assets.
A Phase 1/2 immunoradiotherapy combination study of GEN1042 (a bispecific antibody) with radiotherapy, alone or with pembrolizumab, in participants with metastatic solid tumors has been marked Terminated on ClinicalTrials.gov. No antitumor activity or safety data have been released to explain the termination.
Why it matters
GEN1042's termination in solid tumors suggests the immunoradiotherapy combination strategy did not generate sufficient signal to continue, narrowing Genmab's bispecific antibody pipeline in the solid tumor setting.
Analysis
Genmab has multiple bispecific programs in development, and the termination of this exploratory combination study is not an existential event, but it does close off a differentiated positioning angle — pairing GEN1042 with radiotherapy to trigger local immune activation. Investors should assess whether Genmab's remaining GEN1042 indications, if any, carry enough data to support continued development.
What to watch
Watch for Genmab's next pipeline update to determine whether GEN1042 continues in any other indication or combination setting.
Etigilimab plus nivolumab evaluated in platinum-resistant clear cell ovarian cancer
M.D. Anderson's Phase 2 single-arm study of etigilimab (an anti-TIGIT antibody) combined with nivolumab in platinum-resistant epithelial ovarian cancer remains active but not yet recruiting, with no efficacy data disclosed.
Why it matters
Platinum-resistant ovarian cancer has extremely limited treatment options; if dual checkpoint blockade targeting PD-1 and TIGIT (an immune checkpoint receptor) generates durable responses in clear cell histology, it could validate combination immunotherapy in a subtype historically considered immunologically cold.
Analysis
TIGIT-targeted combinations had a turbulent period following high-profile Phase 3 failures in lung cancer, making any positive signal in ovarian cancer — even in a single-arm Phase 2 — potentially meaningful for resetting investor expectations around the TIGIT mechanism. The academic sponsorship by M.D. Anderson, rather than an industry sponsor, suggests this is exploratory hypothesis-testing rather than a registration-enabling strategy.
What to watch
Watch for M.D. Anderson to present preliminary response rate data from this study at SGO or ESMO Gynaecological Oncology in late 2026 or early 2027.
Sangamo CAR-Treg cell therapy study in living-donor kidney transplant marked complete
Sangamo Therapeutics' Phase 1/2 study of TX200-TR101 — chimeric antigen receptor-modified regulatory T-cells (CAR-Tregs, engineered immune cells designed to prevent organ rejection) — in living-donor kidney transplant recipients has been marked Completed on ClinicalTrials.gov, with no safety or efficacy data yet disclosed publicly.
Why it matters
CAR-Treg therapy represents a potentially paradigm-shifting approach to transplant tolerance, aiming to reduce or eliminate lifelong immunosuppression; completion of this first-in-human study sets the stage for the first meaningful safety and tolerability dataset in this novel cell therapy class.
Analysis
Sangamo's CAR-Treg program has been one of the more scientifically novel assets in the transplant immunology space, and study completion means a data package should be forthcoming — the results will be closely watched by both transplant immunologists and cell therapy investors to determine whether the approach is feasible and safe enough to advance. A clean safety profile, even without formal efficacy endpoints at this stage, would be a meaningful de-risking event.
What to watch
Watch for Sangamo to present TX200-TR101 Phase 1/2 safety and immunological data at the American Transplant Congress or a comparable meeting in the second half of 2026.
Ionis sapablursen Phase 2 in polycythemia vera marked complete
Ionis Pharmaceuticals' Phase 2 study of sapablursen — an antisense inhibitor of TMPRSS6, a gene that regulates iron availability — in phlebotomy-dependent polycythemia vera (a blood disorder causing excess red blood cell production) has been marked Completed on ClinicalTrials.gov, with no efficacy data publicly released.
Why it matters
Polycythemia vera management relies heavily on phlebotomy and cytoreductive drugs; a therapy that reduces phlebotomy frequency by modulating iron-sensing pathways would address a real unmet need and could compete with ruxolitinib in patients intolerant of or resistant to JAK inhibition.
Analysis
Ionis has been expanding its RNA-targeting platform into hematology, and sapablursen's Phase 2 completion in polycythemia vera positions the company for a potential Phase 3 decision — the key question will be whether the magnitude of phlebotomy reduction is large enough to be clinically meaningful and to differentiate from existing options. Investors should watch for data disclosure to assess whether this becomes a priority program.
What to watch
Watch for Ionis to disclose sapablursen Phase 2 efficacy and safety data, potentially at ASH 2026 or in a peer-reviewed publication, and for any announcement of Phase 3 plans.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
MapLight's Phase 2 randomized, placebo-controlled study of ML-007C-MA in inpatient adults with schizophrenia has been marked Completed on ClinicalTrials.gov. No efficacy or safety data have been released; the registry update confirms study closure but tells investors nothing about whether the drug worked.
ClinicalTrials.gov ↗